<p>Drug major Sun Pharma on Tuesday said its arm DUSA Pharmaceuticals has reached a resolution with the US Department of Justice (DOJ) concerning the promotion of Levulan Kerastick and BLU-U on payment of USD 20.75 million (around Rs 148.51 crore)</p>.<p>"DUSA fully cooperated with DOJ in its investigation of a complaint filed by a former employee in September 2016,” Sun Pharmaceutical Industries said in a regulatory filing.</p>.<p>Under the civil settlement agreements signed with the DOJ, DUSA will pay USD 20.75 million to resolve allegations related to the promotion of Levulan Kerastick (aminolevulinic acid HCL) and BLU-U, it stated.</p>.<p>The product is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.</p>.<p>Sun Pharma said DUSA had already made a provision towards this in its fourth quarter financials for the year ended March 31, 2020.</p>.<p>"The settlement does not constitute any admission by DUSA of any liability or wrongdoing", the company added.</p>.<p>As part of the resolution, DUSA and Sun Pharma have entered into a corporate integrity agreement with the Office of Inspector General of the US Department of Health and Human Services.</p>.<p>Under the settlement pact, the DOJ has agreed not to bring any action seeking to exclude DUSA or Sun Pharma from participating in Federal health care programs.</p>.<p>In a separate agreement, Sun Pharma said DUSA also fully resolved all allegations made by the former employee.</p>.<p>Shares of Sun Pharma were trading 0.18 per cent lower at Rs 532.40 apiece on BSE.</p>
<p>Drug major Sun Pharma on Tuesday said its arm DUSA Pharmaceuticals has reached a resolution with the US Department of Justice (DOJ) concerning the promotion of Levulan Kerastick and BLU-U on payment of USD 20.75 million (around Rs 148.51 crore)</p>.<p>"DUSA fully cooperated with DOJ in its investigation of a complaint filed by a former employee in September 2016,” Sun Pharmaceutical Industries said in a regulatory filing.</p>.<p>Under the civil settlement agreements signed with the DOJ, DUSA will pay USD 20.75 million to resolve allegations related to the promotion of Levulan Kerastick (aminolevulinic acid HCL) and BLU-U, it stated.</p>.<p>The product is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.</p>.<p>Sun Pharma said DUSA had already made a provision towards this in its fourth quarter financials for the year ended March 31, 2020.</p>.<p>"The settlement does not constitute any admission by DUSA of any liability or wrongdoing", the company added.</p>.<p>As part of the resolution, DUSA and Sun Pharma have entered into a corporate integrity agreement with the Office of Inspector General of the US Department of Health and Human Services.</p>.<p>Under the settlement pact, the DOJ has agreed not to bring any action seeking to exclude DUSA or Sun Pharma from participating in Federal health care programs.</p>.<p>In a separate agreement, Sun Pharma said DUSA also fully resolved all allegations made by the former employee.</p>.<p>Shares of Sun Pharma were trading 0.18 per cent lower at Rs 532.40 apiece on BSE.</p>